Patterns of Real-World Isavuconazole Use, Effectiveness, Safety, and Healthcare Resource Utilization-a Retrospective Chart Review Study of Patients With Mucormycosis or Invasive Aspergillosis (PRISMA)
Latest Information Update: 21 Mar 2024
At a glance
- Drugs Isavuconazonium (Primary)
- Indications Aspergillosis; Zygomycosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRISMA
- Sponsors Pfizer
- 18 Mar 2024 Status changed from recruiting to completed.
- 20 May 2021 Status changed from not yet recruiting to recruiting.
- 18 Sep 2020 New trial record